Vital voices: Personal stories of treatment for hepatitis C is informed by the sociology of health and illness. In conducting the research and designing the website, the team drew on literature that understands hepatitis C and hepatitis C treatment within their social context. Key works include:
Bryant, J., Rance, J., Hull, P., Mao, L., & Treloar, C. (2019). Making sense of ‘side effects’: Counterpublic health in the era of direct-acting antivirals. International Journal of Drug Policy, 72, 77–83.
de Graaff, B., Yee, K. C., & Clarke, P. (2018). Uptake of and expenditure on direct-acting antiviral agents for hepatitis C treatment in Australia. Applied Health Economics and Health Policy, 16, 495–502.
Crowley, D., Cullen, W., Lambert, J., & Van Hout, M. C. (2019). Competing priorities and second chances: A qualitative exploration of prisoners’ journeys through the Hepatitis C continuum of care. PLOS ONE, 14(9), Article e0222186.
Fraser, S. (2010). Hepatitis C and the limits of medicalisation and biological citizenship for people who inject drugs. Addiction Research and Theory, 18(5), 544–556.
Fraser, S. (2011). Beyond the ‘potsherd’: The role of injecting drug use-related stigma in shaping hepatitis C. In S. Fraser & D. Moore (Eds.), The drug effect: Health, crime and society (pp. 91–105). Cambridge University Press.
Fraser, S., & Moore, D. (2011). Harm reduction and hepatitis C: On the ethics and politics of prevention and treatment. Addiction Research and Theory, 19(4), 375–379.
Fraser, S., & Seear, K. (2016). Making disease, making citizens: The politics of hepatitis C (2nd ed.). Routledge. (Original work published 2011)
Fraser, S., & Treloar, C. (2006). ‘Spoiled identity’ in hepatitis C infection: The binary logic of despair. Critical Public Health, 16(2), 99–110.
Fraser, S., Treloar, C., Bryant, J., & Rhodes, T. (2014). Hepatitis C prevention education needs to be grounded in social relationships. Drugs: Education, Prevention and Policy, 21(1), 88–92.
Goodyear, T., Ti, L., Carrieri, P., Small, W., & Knight, R. (2020). “Everybody living with a chronic disease is entitled to be cured”: Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs. International Journal of Drug Policy, 81, Article 102766.
Goutzamanis, S., Doyle, J., Higgs, P., & Hellard, M. (2019). Improving hepatitis C direct-acting antiviral access and uptake: A role for patient-reported outcomes and lived experience. Journal of Viral Hepatitis, 26(2), 218–223.
Goutzamanis, S., Horyniak, D., Doyle, J., Hellard, M., & Higgs, P. (2021). Perceived physical health outcomes of direct-acting antiviral treatment for hepatitis C: A qualitative study. Harm Reduction Journal, 18, Article 73.
Harris, M. (2017). Managing expense and expectation in a treatment revolution: Problematizing prioritisation through exploration of hepatitis C treatment ‘benefit’. International Journal of Drug Policy, 47, 161–168.
Harris, M., & Rhodes, T. (2013). Hepatitis C treatment access and uptake for people who inject drugs: A review mapping the role of social factors. Harm Reduction Journal, 10, Article 7.
Harris, M., & Rhodes, T. (2018). Caring and curing: Considering the effects of hepatitis C pharmaceuticalisation in relation to non-clinical treatment outcomes. International Journal of Drug Policy, 60, 24–32.
Heard, E., Smirnov, A., Massi, L., & Selvey, L. (2021). Personal, provider and system level barriers and enablers for hepatitis C treatment in the era of direct-acting antivirals” Experiences of patients who inject drugs accessing treatment in general practice settings in Australia. Journal of Substance Abuse Treatment, 127, Article 108460.
Hopwood, M., & Treloar, C. (2005). The experience of interferon-based treatments for hepatitis C infection. Qualitative Health Research, 15(5), 635–646.
Lafferty, L., Rance, J., Grebely, J., Dore, G., Lloyd, A., & Treloar, C. (2020). Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention in the prison setting. International Journal of Drug Policy, 77, Article 102693.
Lafferty, L., Rance, J., & Treloar. C. (2018). Who goes first? Understanding hepatitis C risk among injecting networks in the prison setting. Drug and Alcohol Dependence, 183, 96–101.
Madden, A., Hopwood, M., Neale, J., & Treloar, C. (2018). Beyond cure: Patient reported outcomes of hepatitis C treatment among people who inject drugs in Australia. Harm Reduction Journal, 15, Article 42.
Madden, A., Hopwood, M., Neale, J., & Treloar, C. (2018). Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs? PLOS ONE, 13(11), Article e0207226.
Pourmarzi, D., Smirnov, A., Hall, L., FitzGerald, G., & Rahman, T. (2020). ‘I’m over the moon!’: Patient-perceived outcomes of hepatitis C treatment. Australian Journal of Primary Health, 26(4), 319–324.
Rance, J., Lafferty, L., & Treloar, C. (2020). ‘Behind closed doors, no one sees, no one knows’: Hepatitis C, stigma and treatment-as-prevention in prison. Critical Public Health, 30(2), 130–140.
Rance, C., Rhodes, T., & Lancaster, K. (2021). Pharmaceutical citizenship in an era of universal access to hepatitis C treatment: Situated potentials and limits. Health: An Interdisciplinary Journal for the Social Study of Health, Illness and Medicine. Advance online publication.
Richmond, J., Ellard, J., Thorpe, R., Higgs, P., Hellard, M., & Thompson, A. (2018). Achieving a hepatitis C cure: A qualitative exploration of the experiences and meanings of achieving a hepatitis C cure using direct acting antivirals in Australia. Hepatology, Medicine and Policy, 3, Article 8.
Seear, K., Fraser, S., Farrugia, A., & valentine, k. (2020). Beyond a ‘post-cure’ world: Sketches for a new futurology of hepatitis C. International Journal of Drug Policy, 94, Article 103042.
Seear, K., Fraser, S., & Lenton, E. (2010). Guilty or angry? The politics of emotion in accounts of hepatitis C transmission. Contemporary Drug Problems, 37(4), 619–638.
Seear, K., & Lenton, E. (2021). Becoming posthuman: Hepatitis C, the race to elimination and the politics of remaking the subject. Health Sociology Review, 30(3), 229-243.
Treloar, C., Jackson, C., Gray, R., Newland, J. Wilson, H., Saunders, V., Johnson, P., & Brener, L. (2016). Multiple stigmas, shame and historical trauma compound the experience of Aboriginal Australians living with hepatitis C. Health Sociology Review, 25(1), 18–32.
Treloar, C., Rance, R., & Backmund, M. (2013). Understanding barriers to hepatitis C virus cure and stigmatization from a social perspective. Criminal Infectious Diseases, 47(2), S51–S58.
Treloar, C., Rance, R., Bryant, J., & Fraser, S. (2016). Understanding decisions made about hepatitis C treatment by couples who inject drugs. Journal of Viral Hepatitis, 23(2), 89–95.
Williams, B., Nelons, D., Seaman, A., Witkowska, M., Ronan, W., Wheelock, H., Zaman A., Garcia, J. (2019). Life projects: The transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs. Injectional Journal of Drug Policy, 72, 138–145.
Winter, R., Fraser, S., Booker, N., & Treloar, C. (2011). Technical review of hepatitis C health promotion resources (Monograph 5/2011). National Centre in HIV Social Research, The University of New South Wales.
Winter, R., Fraser, S., Booker, N., & Treloar, C. (2013). Authenticity and diversity: Enhancing Australian hepatitis C prevention messages. Contemporary Drug Problems, 40(4), 505–529.
Wright, C., Cogger, S., Hsieh, K., Goutzamanis, S., Hellard, M., & Higgs, P. (2019). “I’m obviously not dying so it’s not something I need to sort out today”: Considering hepatitis C treatment in the era of direct acting antivirals. Infection, Disease and Health, 24(2), 58–66.